Patient Journey Articles                                          Patient Journey Videos

Our Mission
To document the
Patient Journey from (1) the perspective of the patient and (2) the perspective of the clinician or other health professionals, while always retaining the focus on the patient during their passage through the health system.
  1. Multiple Sclerosis-Breea's Story
    Multiple sclerosis is an autoimmune disease that affects the brain and spinal cord (central nervous system). Multiple sclerosis (MS), also known as "disseminated sclerosis" or " encephalomyelitis disseminata", is an inflammatory disease in which the fatty myelin sheaths covering nerves in the brain and spinal cord are attack. Multiple sclerosis affects 2.5 million people worldwide, including 400000 Americans. Few of these are young adults and less rare are teens. Fewer still are those with a catostrophic onset. This is what happened to Breea Renee. This video shares her story, her journey back from being paralyzed and blind on her left side, and proves that with determination and laughter, the love of family and friends, and the right medical team, healing is possible!
  2. Navigating the Acute Myeloid Leukemia (AML) Patient Journey
    Acute myeloid leukemia (AML) patient, Arne Jensen, tells his story from diagnosis to adjusting to life after AML.
  3. Emerging Treatments for Acute Myelogenous Leukemia
    Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses treatment options for acute myelogenous leukemia (AML), which comprise a variety of chemotherapy regimens and stem cell transplantation. Current standard chemotherapy regimens cure only a minority of patients with AML. As a result, all patients should be evaluated for entry into well-designed clinical trials. Actinium's Iomab-B is intended to be an induction and conditioning agent prior to a bone marrow transplant (BMT), often referred to as a hematopoietic stem cell transplant (HSCT) with an initial indication in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above.
  4. Biomarkers and Type 1 Gaucher Disease
    The use of biomarkers can provide valuable insight into the molecular pathogenesis of lysosomal storage diseases such as Gaucher disease and Fabry disease. Dr. Pramod Mistry discusses biomarkers as they pertain to patients with type 1 Gaucher disease.
Patient Journey Maps
Download Patient Journey Map for Multiple Sclerosis

Join our newsletter